An Unbiased View of Premarket Notification 510(k)
(iv) A short description of the overall plan for investigating the drug product or service for the subsequent 12 months. The system should really include things like the next:Thus, Even though FDA's critique of Section 1 submissions will concentrate on assessing the safety of Stage 1 investigations, FDA's critique of Phases 2 and 3 submissions may